Physician profile
Chris Nelson
NPI 1255369674
$2,183.11
in general payments reported to CMS, 2019-2025
15 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $99.99 · 2023: $541 · 2024: $752 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $271.68 | 2021-2024 | Dexcom G7 Gss (161) |
| Genzyme Corporation | $246.81 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $245.13 | 2023-2025 | Austedo Xr, Austedo Xr |
| Gilead Sciences, INC. | $224.98 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $123.13 | 2024 | Wainua |
| Averitas Pharma INC. | $121.80 | 2023 | Qutenza |
| Viiv Healthcare Company | $121.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $120.39 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $115.06 | 2024 | Spravato |
| Medtronic, INC. | $113.03 | 2024 | Interstim |
| Agile Therapeutics, INC. | $111.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $97.46 | 2021 | |
| Neurocrine Biosciences, INC. | $94.11 | 2021 | |
| Exact Sciences Corporation | $51.68 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.